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In the adult mouse brain, neurogenesis occurs continuously in
at least two regions: the subventricular zone (SVZ) of the
lateral ventricle (Altman, 1963, 1969; Doetsch et al., 1997) and
the subgranular zone of the hippocampal dentate gyrus (Seki
and Arai, 1993; Eriksson et al., 1998). In the adult SVZ, subsets
of glial fibrillary acidic protein positive (GFAP+) cells (type B
cells) function as quiescent neural stem cells (Doetsch et al.,
1999), although a portion of these cells are slowly dividing at
any given time. These quiescent cells qualify as being activated
when they begin to co-express the epidermal growth factor
receptor (EGF-R) and come into contact with the ventricle
(Pastrana et al., 2009). Then, they give rise to rapidly
proliferating cells called “transit-amplifying cells” (type C
cells), which stop expressing GFAP but still express EGF-R. The
cells then differentiate into doublecortin (DCX)-expressing
neuroblasts (type A cells) that migrate along the rostral
migratory stream (RMS) towards the olfactory bulb (Lois and
Alvarez-Buylla, 1994; Petreanu and Alvarez-Buylla, 2002).
They finally integrate into both the granule cell layer (GCL)
and glomerular layer (GL) of the olfactory bulb, where they
express mature neuronal markers, such as NeuN (Winner et al.,
2002).
The early signaling cues promoting the proliferation and
differentiation of the neural stem and progenitor cells (NSPCs)
are yet to be elucidated. Recent studies have proposed that
blood vessels are critical elements of the neurogenic niches in
both the hippocampus (Palmer et al., 2000) and the SVZ
(Mercier et al., 2002; Shen et al., 2008; Tavazoie et al., 2008).
In addition, Mercier et al. (2002) previously characterized basal
lamina-like structures, termed fractones, in the vicinity of
NSPCs in the adult SVZ. Fractones present extracellular
branched fractal structures in direct contact with NSPCs in
the adult neurogenic niche, thereby suggesting fractones' role
in neurogenesis (Altman, 1963, 1969; Doetsch et al., 1997;
Mercier et al., 2002, 2003).
Fractones are composed of different extracellular
matrix (ECM) molecules, such as laminin (β1 and γ1 but
not α1), collagen IV, nidogen, and perlecan (Mercier et al.,
2002; Kerever et al., 2007). They are able to capture/bind
the neurogenic growth factor FGF-2 from the extracellular
environment. This trapping of FGF-2 involves binding to
heparan sulfate chains (Kerever et al., 2007; Douet et al.,
2012). Furthermore, FGF-2 promotes neurogenesis in
developing (Raballo et al., 2000; Maric et al., 2007;
Pastrana et al., 2009) and adult brains (Lois and
Alvarez-Buylla, 1994; Palmer et al., 1995; Petreanu and
Alvarez-Buylla, 2002).
We previously showed that perlecan (HSPG2), a major
heparan sulfate proteoglycan (HSPG) in basement mem-
branes, is present in both blood vessel walls and fractones
in the neurogenic niche (Kerever et al., 2007). Perlecan
interacts with extracellular molecules, growth factors, and
cell surface receptors (Rapraeger, 1995; Winner et al., 2002;
Chan et al., 2009), and is implicated in many biological
functions in tissue development, homeostasis, and diseases
(Arikawa-Hirasawa et al., 1995, 1999; Palmer et al., 2000;
Arikawa-Hirasawa et al., 2001, 2002a, 2002b; Xu et al., 2010).
Perlecan promotes growth factor receptor binding, such as
FGF-2, to stimulate mitogenesis and angiogenesis (Yayon et
al., 1991; Aviezer et al., 1994; Mercier et al., 2002; Shen etal., 2008; Tavazoie et al., 2008). A perlecan analog in
Drosophila has also been implicated in the reactivation of
proliferation in quiescent neural stem cells (NSCs) (Voigt et
al., 2002).
Perlecan deficiency causes perinatal lethal chondrodysplasia
in mice and in humans (Arikawa-Hirasawa et al., 1999; Costell
et al., 1999; Arikawa-Hirasawa et al., 2001), and perlecan
knockout (HSPG2−/−) mice present impaired indian hedgehog
expression and FGF-1 signaling and abnormal cephalic develop-
ment (Arikawa-Hirasawa et al., 1999). HSPG2−/− mice die at
or just before birth due to defects in tracheal cartilage.
Furthermore, Giros and colleagues reported a disrupted
distribution of sonic hedgehog (Shh) and impaired forebrain
development in perlecan-null mice (Girós et al., 2007). We
previously created perinatal lethality rescued (Hspg2−/−-Tg)
mice by expressing recombinant perlecan specifically in the
cartilage of the perlecan-null (HSPG2−/−) genetic background,
in order to study the role of perlecan in tissue homeostasis in
adult mice. We used these HSPG2−/−-Tg mice to show that
perlecan is critical for maintaining fast muscle mass and fiber
composition, through regulation of myostatin signaling (Xu et
al., 2010).
In the present report, we studied the role of perlecan in the
maintenance and fate of NSCs, and in response to FGF-2
stimulation in the SVZ of Hspg2−/−-Tg mice. The absence of
perlecan resulted in the depletion of CD133+ NSCs. In addition,
FGF-2 treatment failed to induce an increase in activation of
Akt and Erk1/2 pathways both in vivo and in vitro in the
absence of perlecan. Furthermore, FGF-2 failed to induce
cyclin D2 expression and to promote the formation of
neurospheres. Taken together, our results indicate that the
absence of perlecan is detrimental for CD133+ NSC population
and for adult neurogenesis, suggesting that it is a critical
component of the adult neurogenic niche.
Materials and methods
Animals
Perlecan-null (Hspg2−/−) mice die at birth because of premature
cartilage development (Arikawa-Hirasawa et al., 1999). To
restore cartilage abnormalities, we used a cartilage-specific
Col2a1 promoter/enhancer to generate a perlecan transgenic
mouse line (WT-Tg, Hspg2+/+; Col2a1-Hspg2Tg/-), which
expressed recombinant perlecan in cartilage (Tsumaki et al.,
1999). We subsequently created lethality-rescued mice
(Hspg2−/−-Tg, Hspg2−/−; Col2a1-Hspg2Tg/-) by mating the
transgenic mice with heterozygous Hspg2+/− mice (Xu et al.,
2010). We maintained these mice on the mixed genetic
background of C57BL/6 and 129SvJ. In this study, WT-Tg mice
(control) and Hspg2−/−-Tg (perlecan knockout) mice were
used. All animal protocols were approved by the Animal Care
and Use Committee of Juntendo University.
BrdU incorporation and FGF-2 treatment assays
Mice that were 8–12 weeks old were used in this study.
Nine-week-old mice were sacrificed 48 h after intracerebro-
ventricular (ICV) injection of BrdU (1 μl of 40 mg/ml;
WT-Tg, n = 5; Hspg2−/−-Tg, n = 5). Eight-week-old mice
received daily intraperitoneal injections of BrdU (50 mg/kg
494 A. Kerever et al.of body weight) for 5 days. They were sacrificed 4 weeks after
the fifth and last injections (WT-Tg, n = 5; Hspg2−/−-Tg,
n = 5). For FGF-2 stimulation in NSCs, 9-week-old mice were
injected ICV with FGF-2 (1 μl, 0.075 μg/μl). Mice were
sacrificed 48 h after ICV injections.Histology
Mice were deeply anesthetized and perfused transcardially
with cold paraformaldehyde (4%) in a 100 mM phosphate
buffer, pH 7.4. Brains were dissected, immersed overnight
in fixative, and transferred to 30% sucrose for at least 48 h.
Brains were frozen and cut into 25 μm coronal sections with
a cryostat. For extracellular matrix staining, fresh brains
were frozen in isopentane. Sections were stored at −20 °C
until staining.Immunofluorescence
Sections were post-fixed in cold paraformaldehyde for 10 min
and washed in PBS. Sections were then placed in a 0.5% Triton
X-100/PBS solution for 15 min, followed by 15 min of a
blocking solution (0.2% gelatin/PBS). Primary antibodies
were applied for either 2 h at room temperature or overnight
at 4 °C in blocking solution. The following primary antibody
dilutions were used: rat anti-perlecan (1:400, clone A7L6,
Chemicon, Temecula, CA), rabbit polyclonal anti-laminin
(1:1000, Sigma, St Louis, MO), rabbit polyclonal anti-agrin
(1:1000, kind gift of Dr. Sasaki, add his location), mouse
anti-heparan sulfate (10E4 epitope, 1:400, Seikagaku Corpo-
ration, Tokyo, Japan), mouse anti-heparan sulfate (JM403
epitope, 1:400, Seikagaku Corporation, Tokyo, Japan), mouse
anti-delta heparan sulfate (3G10 epitope, 1:400, Seikagaku
Corporation, Tokyo, Japan), mouse anti-chondroitin sulfate
(CS-56) (1:400, Abcam, Cambridge, MA), rat anti-CD133
(1:50, Chemicon, Temecula, CA), rabbit anti-GFAP (1:400,
Dako, Glostrup, Denmark), mouse anti-GFAP conjugated to
alexafluor 647 (1:400, Cell Signaling Tech, Boston, MA), rabbit
polyclonal anti-EGF-Receptor (1:200, Chemicon, Temecula,
CA), goat anti-doublecortin (DCX) (1:200, Santa Cruz
Biotechnology, Santa Cruz, USA), mouse anti-NeuN (1:200,
Chemicon, Temecula, CA) and rabbit anti-ssDNA (1:200,
Immuno-Biological Laboratories Co, Fujioka, Gunma, Japan).
Sections were then rinsed, and secondary antibodies were
applied for 40 min at room temperature. The following
fluorochrome-conjugated secondary antibody dilutions were
used: donkey anti-mouse-CY5, donkey anti-goat-FITC (1:400,
Jackson ImmunoResearch Laboratories, West Grove, USA),
goat anti-rabbit alexafluor-488, and goat anti-mouse-FITC
(1:400 Molecular probes, Invitrogen Corporation, Carlsbad,
USA). Sections were rinsed in PBS before being treated in 2 N
HCl for 30 min at 37 °C and then incubated for 10 min in a
0.1 M borate buffer (pH 8.5). Sections were rinsed before
overnight incubation in rat anti-BrdU (1:800, AbD Serotec,
MorphoSys AG, Planegg, Germany). Sections were rinsed and
then incubated for 1 h with donkey anti-rat-CY3 (1:400,
Jackson, ImmunoResearch Laboratories, West Grove, USA).
Sections were rinsed and then incubated for 10 min in
bis-benzimide (1:3000, Molecular Probes, Invitrogen Corpora-
tion, Carlsbad, CA). After extensive washes, sections weremounted in fluoro-gel with tris buffer (Electron Microscopy
Sciences, Hatfield, USA).
Flow cytometry analysis
SVZs from 12-week-old WT-Tg and Hspg2−/−-Tg mice (n = 3)
were carefully dissected following the procedure described by
Fischer and colleagues (Fischer et al., 2011). SVZs were then
cut into small pieces and incubated for 15 min with a papain
neural tissue dissociation kit from Miltenyi (Auburn, CA, USA).
Cells were mechanically dissociated and passed through a
40 μm cell strainer. After washing in stain buffer (BD
Bioscience, San Jose, CA, USA), the cells were incubated for
30 min in 50 μl of stain buffer with anti CD133-PE (1:20,
eBioscience, San Diego, CA, USA) and with alexafluor-488-
conjugated EGF (1:20, Molecular probes, Eugene, OR, USA).
Cells were then fixed and permeabilized (BD Cytofix/
Cytoperm kit, BD Biosciences, San Jose, CA, USA) prior to
incubation with alexafluor-647 GFAP (1:40, Cell Signaling
Technology, Danvers, MA, USA). Cells were washed and
resuspended in 500 μl of stain buffer to perform flow
cytometry analysis. The analysis was performed using a BD
LSR Fortesa cell analyzer with the gate set using an
appropriate isotype control.
Neurosphere culture
The cortexes of E16.5 mice were dissected and mechanically
dissociated to single cell suspension. Cells were plated for
4 h to allow adherent cells to attach to the plate in DMEM/
F12 and B27. Cells in suspension were recovered, counted
and placed in 96 well plates at low density (300 cells/well)
in 200 μl of DMEM/F12 and B27 containing EGF 20 ng/ml
and different concentrations of FGF-2. Conditions were as
follows: no FGF-2, control (FGF-2 20 ng/ml), and 10X FGF-2
(FGF-2 200 ng/ml). After one week in culture, the number
and the size of neurospheres in each well were assessed.
For differentiation, primary neurospheres were cultured
for an additional 7 days on collagen-1 coated slide chambers
with DMEM/F12 and 10% fetal calf serum prior to fixation
in 10% PFA. Differentiated cells were then stained with
GFAP, Tuj-1, and O4. Whole neurospheres were fixed in
PFA (10 min) prior to immunocytochemistry as described
above.
Western blotting
Whole SVZ or neurospheres were lysed in RIPA buffer (0.5%
deoxycholate, 0.1% SDS, 250 mM NaCl, 25 mM Tris–HCl,
pH 8, Igepal CA630, 5 mM EDTA, protease inhibitor and
phosphostop; sonication 3 times 5 s). Lysates were boiled
in an LDS-sample buffer (Invitrogen) with DTT for 10 min.
The samples were loaded on 4–12% polyacrylamide Bis-Tris
gels (Invitrogen). After electrophoresis, the proteins were
transferred to a PVDF membrane (Invitrogen). The mem-
brane was blocked with 5% skim milk in Tris-buffered
saline-0.1% Tween 20, and incubated with the indicated
antibodies. Primary antibodies used in Western blotting were
Akt (rabbit polyclonal, Cell signaling), phospho-Akt (mouse IgG,
Cell signaling), Erk1/2 (rabbit polyclonal, Cell signaling),
phospho-Erk1/2 (rabbit polyclonal, Cell signaling). Secondary
Figure 1 Extracellular matrix content in the SVZ. (A, B) Confocal images of the lateral ventricle of control (WT-Tg) and
lethality-rescued perlecan-null mice (Hspg2−/−-Tg), showing staining with perlecan (green), laminin-111 (polyclonal, red) and DAPI
(blue). Perlecan expression co-localized with laminin on all blood vessels (arrowhead) and fractones (arrow) in the WT-Tg mice, but
was absent in the Hspg2−/−-Tg. (B, C, D) High magnification of the SVZ. The ependymal wall is on the right of each image and the
parenchyma on the left. (C) Agrin (red) display co-localizes with laminin and perlecan while collagen 18 expression (green) is
restricted to parenchymal (distance from the ventricle N 50 μm) or large (diameter N 30 μm) blood vessels. Collagen 18 was absent
from SVZ capillaries (arrowhead) and from fractones (arrow). (D) The N-sulfated heparan sulfate marker (10E4, green) is strongly
present in fractones (arrow) and in SVZ blood vessels (arrowhead), but its expression greatly decreases in the parenchymal blood
vessels. Scale bar is 50 mm in A and 20 μm in B, C, and D.
495Perlecan is required for FGF-2 signaling in the neural stem cell nicheantibodies were rabbit IgG-HRP (Amersham) and mouse
IgG-HRP (Amersham). SuperSignal West Dura Chemilumines-
cent Substrate (Thermo Scientific) was used to detect
proteins.Quantitative real time PCR
RNA from either whole SVZ or neurospheres was extracted
using TRIzol reagent (Invitrogen). cDNA was synthetized
496 A. Kerever et al.using the RT2 First stand kit from Qiagen. Real time PCR
was performed using RT2 qPCR primer assays and RT2
SYBR green mastermix from Qiagen on a Fast 7500 Real
Time Cycler (Applied Biosystems). Analysis was per-
formed using the web-based application provided by
Qiagen.Quantification and statistical analysis
Analysis was performed using a Leica TCS-SP5 confocal laser
scanning microscope. Whole ventricles were reconstructed
from pictures taken with 20× plan-apochromat dry objec-
tives (0.7). Serial coronal sections of the SVZ between
497Perlecan is required for FGF-2 signaling in the neural stem cell nicheBregma A 1.1 and Bregma A 0.7 were labeled with either
GFAP, CD133, EGF-R, DCX, or BrdU. Cells were counted on
images taken from ventricles using ImageJ (ImageJ 1.45 o,
Wayne Rasband, NIH, USA). CD133+/GFAP+ (for type B cells),
EGF-R+/GFAP+ (for activated type B cells), EGF-R+/GFAP−
(for type C cells), and DCX+ (for type A cells) populations
were quantitated by cell type. Serial coronal sections of the
RMS between Bregma A 3.2 and Bregma A 3.0 were labeled
with DCX, GFAPs, and BrdU. The size of the RMS was assessed
by measuring the cluster of DCX+ cells with ImageJ. Serial
coronal sections of the OB between Bregma A 4.3 and
Bregma A 4.4 were labeled with NeuN, GFAPs, and BrdU. For
neurosphere cultures, statistics were made from 6 wells per
condition per animal (from 6 WT-Tg and 4 Hspg2−/−-Tg
forebrain). Data are presented as the total number of cells
per ventricle (mean ± SEM) and analyzed using the Unpaired
Student's t-test with confidence intervals of 99% or one-way
analysis of variance coupled with the Bonferroni post-test
(Graph-Pad Prism version 5.0 for Mac OS X, Graph-Pad
Software, San Diego, CA).
Results
Perlecan deficiency induces no obvious change in
other ECM components in the neurogenic niche
We studied the role of perlecan in NSCs by first comparing
the ECM content in the SVZ of HSPG2−/−-Tg mice with that of
control mice (WT-Tg; Fig. 1). In control mice, perlecan was
localized in fractones and all blood vessel basement
membranes (SVZ and adjacent neural nuclei). In the
HSPG2−/−-Tg mice, perlecan was completely absent, but
laminin-111 staining, an another basement membrane
component which consists of laminin α1 (Lama1), β1
(Lamb1), and γ1 (Lamc1) chains, was still displayed in
both fractones and blood vessels (Figs. 1A, B). Next, we
investigated other basement membrane heparan sulfate
proteoglycans (HSPGs), such as collagen 18 and agrin. While
agrin displayed the same patterns as laminin-111 and
perlecan, collagen 18 was only expressed in the basement
membranes of blood vessels from neural nuclei adjacent to
the SVZ and was absent in the fractones and SVZ blood
vessel walls of control mice (Fig. 1C).
We also investigated the presence of heparan sulfate (HS)
and chondroitin sulfate (CS) chains. Three types of antibod-
ies to heparan sulfate (HS) chains were used: 10E4 (HSFigure 2 Neural stem cell maintenance in perlecan null mice. (A
lateral ventricle stained with CD133, GFAP and heparan sulfate ch
CD133+GFAP+ NSCs (arrowheads). (B) Shadow projection of a Z-stac
contacting numerous fractones (arrows). (C) Confocal image of the S
and Hspg2−/−-Tg. CD133 is expressed strongly by ependymocytes and
and NSCs. We discriminated SVZ NSCs by counting positive cells for bo
double positive cells in the image for WT-Tg SVZ and two in the imag
CD133+GFAP+ NSCs per ventricles in WT-Tg and Hspg2−/−-Tg. In the
27%. The data are expressed as mean ± SEM (n = 5, *** indicates P-v
characterization of NSCs by flow cytometry analysis and the sepa
(EGF-fraction). (F) Bar chart displaying the number of quiescent NSC
GFAP-) in WT-Tg and Hspg2−/−-Tg SVZ assessed by flow cytometry a
Hspg2−/−-Tg brain. The data are expressed as mean ± SEM (n = 3, * in
Student's t-test). Scale bar: 10 μm. SVZ: subventricular zone; E: epeepitope including N-sulfated glucosamine) (Fig. 1D), JM403
(HS epitope including N-unsubstituted glucosamine) (Sup-
plemental Fig. 1A), and 3G10 (HS neo-epitope generated by
HS chains digestion by heparatinase) (Supplemental Fig. 1B).
Immunostaining with these antibodies showed similar local-
izations of HSs. They were all strongly expressed in fractones
and in SVZ blood vessels, but their expression was substan-
tially weaker in blood vessels outside the SVZ of both WT-Tg
and Hspg2−/−-Tg mice. Antibody CS-56 to CS types A and C
did not stain either fractones or most of the SVZ blood
vessels, but did stain blood vessels of the neural nuclei
adjacent to the SVZ and the pericellular matrix of SVZ cells
(Supplemental Fig. 1C). The absence of perlecan did not
cause any obvious visible change in the expression of these
HS and CS chains in the SVZ. These results suggest that, in
the absence of perlecan, basement membranes exist and
other HS chain-containing basement membrane compo-
nents, such as agrin, are present in fractones and in most
SVZ blood vessels.Perlecan presence is critical for neural stem cell
maintenance and for neurogenesis in the SVZ
We next investigated the maintenance of NSCs and
neurogenesis in the SVZ of Hspg2−/−-Tg mice. We charac-
terized the cell identity with several cell type markers,
such as GFAP, CD133, EGF-R, and DCX. CD133, also known
as Prominin 1 (PROM1), is a marker of cancer stem cells
and has been used to identify NSCs in both humans and
rodents (Uchida et al., 2000; Corti et al., 2007; Mirzadeh
et al., 2008). We used CD133 as a marker for NSCs, in
addition to another NSC marker, GFAP. This combination
allowed us to distinguish NSCs from CD133+
ependymocytes and GFAP+ astrocytes (Fig. 2A, arrow-
heads). These NSCs sent many processes in the direction
of close-by fractones, thus contacting most fractones in
their vicinity (Fig. 2B).
We found a 27% decrease in the number of CD133+ NSCs in
Hspg2−/−-Tg mice (WT-Tg: 83.55 ± 2.60 CD133+/GFAP+ cells
per ventricle, Hspg2−/−-Tg: 61.06 ± 2.60; Figs. 2C,D). This
result was confirmed by flow cytometry analysis of the SVZ.
Both quiescent (CD133+ GFAP+ EGF-R−) and activated
(CD133+ GFAP+ EGF-R+) NSCs were significantly reduced in
the Hspg2−/−-Tg (Figs. 2E,F). The number of activated type B
cells was reduced by 53% in the absence of perlecan (WT-Tg:
5.06 ± 0.22 EGF-R+/GFAP+ cells per ventricle; Hspg2−/−-Tg:) Confocal image of the surface of the ependymal wall of the
ains (10E4) reveals fractones (10E4 staining) in the vicinity of
k of the insert in A (realized with Imaris software) shows NSCs
VZ (striatum side) displaying CD133 and GFAP staining in WT-Tg
is also present in SVZ NSCs. GFAP is expressed by SVZ astrocytes
th CD133 and GFAP in the subependymal layer (arrows show four
e for Hspg2−/−-Tg SVZ. (D) Bar chart displaying the total number
Hspg2−/−-Tg mice CD133+GFAP+ NSC number was decreased by
alue of P b 0.0001; Student's t-test). (E) Dot plot depicting the
ration of activated NSCs (EGF + fraction) and quiescent NSCs
s and activated NSCs (for one hundred ependymocytes CD133+
nalysis. Both quiescent and activated NSCs are reduced in the
dicates P-value of P = 0.0159, ** indicates P-value of P = 0.0069;
ndyma; LV: lateral ventricle.
498 A. Kerever et al.2.35 ± 0.17; Fig. 3B). The number of type C cells was
decreased by 20% (WT-Tg: 37.53 ± 2.01 EGF-R+/GFAP- cells
per ventricle; Hspg2−/−-Tg: 29.94 ± 1.14; Fig. 3C).Figure 3 Neurogenesis in the SVZ of perlecan null mice. (A) Confoca
staining in WT-Tg and Hspg2−/−-Tg mice. The insert shows examples o
magnification (arrowhead). (B) Bar chart indicates the total number o
and Hspg2−/−-Tg mice. In the Hspg2−/−-Tg mice, EGF-R+GFAP+ cell num
EGF-R-GFAP+ cells (type C cells) per ventricle in WT-Tg and Hspg2−/−-T
decreased by 20%. (D) Reconstructed lateral ventricle from a confoca
the lateral ventricle at a higher magnification. Arrowhead shows a dou
number of DCX+ cells (type A cells, E), BrdU+ cells (proliferating cells
WT-Tg and Hspg2−/−-Tgmice. In the Hspg2−/−-Tgmice, DCX+ cell numbe
and newly formed type A cell numbers decreased by 20%. The dat
P b 0.0001; ** indicates P-value of P b 0.01; Student's t-test). Scale bWe also analyzed the neuroblast population (DCX+
cells) and proliferating cells in the SVZ. The number
of neuroblasts decreased by 18% in the absence ofl image of the SVZ (striatum side) showing EGF-R, GFAP, and DAPI
f double positive EGF-R+GFAP+ (activated type B cells) at a higher
f EGF-R+GFAP+ cells (activated type B cells) per ventricle in WT-Tg
bers were decreased by 53%. (C) Bar chart displaying total number
g mice. In the Hspg2−/−-Tg mice, EGF-R+GFAP+ cell numbers were
l image displaying DCX and BrdU staining. Insert shows the horn of
ble-positive DCX+BrdU+ cell. (E, F, G) Bar chart indicates the total
), and DCX+BrdU+ cells (newly born type A cells) per ventricle in
rs decreased by 18%, proliferating cell numbers decreased by 25%,
a are expressed as mean ± SEM (n = 5, *** indicates P-value of
ar: 10 μm in A, 100 μm in D and 30 μm in insert in D.
Figure 4 New neurons in the olfactory bulb in perlecan null mice. (A) Drawing of a sagittal section of a mouse brain showing the
localization of the coronal section (Nissl staining showing the lateral ventricle at bregma A +4). Insert depicts the area where confocal
images in Fig. 5B and D were taken. (B) Confocal image of the granule cell layer (GCL) of the OB displaying NeuN and BrdU staining in
WT-Tg and Hspg2−/−-Tg mice. Dotted lines show the boundary of the GCL. Overall, 95% of BrdU+ cells co-localized with the mature
neuronalmarker NeuN. (C) Bar chart indicates the total number of BrdU+NeuN+ cells (newneurons) in one field (0.624 μm2) of the GCL (5B
represent half of a field). The number of proliferating cells in the GCL decreased by 20% in Hspg2−/−-Tg mice. (D) Confocal image of the
glomerular layer (GL) of the OB indicates NeuN and BrdU staining inWT-Tg and Hspg2−/−-Tgmice. (E) Bar chart indicates the total number
of BrdU+NeuN+ cells (newneurons) in one field (0.312 μm2 as shown in 5D) of the GL. The number of proliferating cells in the GL decreased
by 27% in Hspg2−/−-Tg mice. The data are expressed as means ± SEM (n = 5, *** indicates P-value of P b 0.0001; Student's t-test).
499Perlecan is required for FGF-2 signaling in the neural stem cell nicheperlecan (WT-Tg: 253.80 ± 5.52 DCX+ cells per ventricle;
Hspg2−/−-Tg: 207.3 ± 6.04; Fig. 3E). To detect newly
formed neuroblasts, we analyzed BrdU-positive cells in the
SVZ 48 h after a single BrdU injection into the animals.
We found that the number of proliferating BrdU+ cells
decreased by 25% (WT-Tg: 191.8 ± 4.09 BrdU+ cells per
ventricle; Hspg2−/−-Tg: 144.6 ± 3.92; Fig. 3F). The number
of newly formed neuroblasts (DCX+/BrdU+) also decreased
by 20% in the absence of perlecan (WT-Tg: 100.30 ± 2.54 DCX+
cells per ventricle; Hspg2−/−-Tg: 79.79 ± 2.45; Fig. 3G). These
results indicate that the NSC population was reduced in
the perlecan-deficient SVZ, which ultimately resulted in a
decrease in neurogenesis.Fewer new neurons integrate into the olfactory
bulb in the Hspg2−/−-Tg mice
After exiting the SVZ, neuroblasts migrate toward the
olfactory bulb in the rostral migratory stream (RMS). Thus,
we followed the fate of the generated neuroblasts 4 weeks
after BrdU injection. We found that the RMS size was
reduced by 25% in the absence of perlecan (Supplemental Fig. 2
B, C), in accordance with the lower number of neuroblasts
generated in the SVZ. Moreover, the majority of BrdU+ cells
already exited the RMS and stopped expressing DCX. These
cells were detected in the granule cell layer (GCL) adjacent to
the RMS (Supplemental Fig. 2D). The numbers of BrdU + cells
Figure 5 Cyclin D2 expression and FGF-2-induced activation of Akt and Erk1/2 pathways in vivo. (A) Bar chart indicates lower cyclin
D2 expression in the SVZ of Hspg2−/−-Tg compared to WT-Tg mice (n = 4, *** indicates P-value of P b 0.0001). (B) Whole SVZ lysates
were immunobloted with the indicated antibodies. WT-Tg and Hspg2−/−-Tg mice were either not treated or ICV-injected with 0.5 μg
of FGF-2 for 30 min prior to sacrifice. (C, D) Bar charts indicate that FGF-2 induced a significant increase of the activation of Akt and
Erk1/2 pathways in the WT-tg but not in the Hspg2−/−-Tg mice. The data are expressed as means ± SEM (n = 3, *** indicates P-value of
P = 0.0007, ** indicates P-value of P = 0.0038; Student's t-test).
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absence of perlecan (WT-Tg: 56.12 ± 1.39 BrdU+/NeuN+ cells;
Hspg2−/−-Tg: 45.76 ± 2.46; Fig. 4E).
We then investigated the nature of the BrdU+ cell
population in the olfactory bulb. We found that most BrdU+
cells had begun to express the neuronal marker NeuN (95% of
BrdU+ cell co-expressed NeuN). These new neurons (BrdU+/
NeuN+) were detected in the GCL (Fig. 4B) and the GL (Fig. 4D).
We observed a reduction in the integration of new neurons in
the GCL (WT-Tg: 72.15 ± 1.96 BrdU+/NeuN+ cells; Hspg2−/−-Tg:
57.73 ± 1.79; Fig. 4C) and the GL (WT-Tg: 7.37 ± 0.40 BrdU+/
NeuN+ cells; Hspg2−/−-Tg: 5.36 ± 0.34; Fig. 4E) in the
perlecan-deficient brain. These data confirmed that the
decrease of CD133+ NSCs observed in the perlecan-deficient
brain leads to fewer new neurons in the olfactory bulb. Our
results show that perlecan is necessary for the maintenance of
the CD133+ NSC population, and for neurogenesis.Perlecan is necessary for FGF-2-induced activation of
Akt and Erk1/2 pathways in the subventricular zone
To understand the reason why early events of neurogenesis
were impaired in the absence of perlecan, we investigated the
expression level of cyclin D2. Cyclin D2 is a protein regulating
cell cycle progression in NSPCs. Its expression is necessary for
entry into the G1/S phase of the cell cycle.We found that cyclin
D2 expression was significantly reduced in the Hspg2−/−-Tg
mice (Fig. 5 A). Perlecan is widely recognized as an HSPG
modulator of FGF-2 signaling (Aviezer et al., 1994; Rapraeger,1995). To understand how perlecan regulates FGF-2 activity in
the neural stem cell niche, we investigated the activation of
the Akt and Erk1/2 pathways in the SVZ after FGF-2 ICV
injection. We found that FGF-2 stimulation induced increased
phosphorylation of both Akt and Erk1/2 proteins in the WT-Tg
mice. However, FGF-2 stimulation failed to activate these two
pathways in the absence of perlecan (Fig. 5 B–D). These results
indicate that perlecan is necessary for the FGF-2-induced
activation of Akt and Erk1/2 pathways in vivo.Neural stem cells express perlecan and can bind
FGF-2 in vitro
To further investigate the role of FGF-2 on NSCs, we cultivated
neurospheres from the cortex of both E16.5WT-Tg andHspg2−/−
-Tg mice. Perlecan was detected in the neurospheres, where its
localizationwas found on the surface of cells that also expressed
N-sulfated HS chains (10E4 epitope, Fig. 6A). These cells often
coexpressed the stem cell marker CD133 (Fig. 6B). Further-
more, biotinylated FGF-2 was mainly captured by those cells
expressing perlecan, 10E4, and CD133. Over 80% of cells that
captured FGF-2 also expressed perlecan. However, FGF-2 was
not found on the surface of cells expressing chondroitin sulfate
chains (Fig. 6C, arrows). This indicates that within the
neurosphere CD133+ putative NSCs are surrounded by ECM
molecules, such as perlecan and HS chains, and are able to
capture FGF-2. To confirm the differentiation potentials of
neurospheres, we cultured the primary neurospheres for an
additional seven days in the absence of a growth factor.
Figure 6 CD133+ NSCs in neurospheres express perlecan and heparan sulfate chains and can capture FGF-2. (A–C) Confocal images
of E16.5 WT-Tg neurosphere stained for perlecan, heparan sulfate chains (10E4), CD133, FGF-2, and chondroitin sulfate chains
(CS56). Arrowheads point out cells within the neurosphere that co-express perlecan and 10E4 in A, CD133 and 10E4 in B. In C,
arrowhead shows that FGF-2 localizes to the surface of cells expressing perlecan but not on the surface of cells that only express
chondroitin sulfate chains (arrows). (D) Confocal image of a differentiated neurosphere displaying neurons (stained with Tuj-1), an
oligodendrocyte (stained with O4), and astrocytes (stained with GFAP). Scale bar: 10 μm.
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astrocytes (Fig. 6D).Perlecan regulates FGF-2 promotion of neurosphere
formation
Since FGF-2 activated Akt and Erk1/2 pathways in the SZV of
WT-Tg mice but not Hspg2−/−-Tg mice, we investigated the
effect of FGF-2 on the formation of neurospheres derivedfrom the cortex of both E16.5 WT-Tg and Hspg2−/−-Tg mice
at different concentrations of FGF-2 (0, 20 and 200 ng/ml).
The number of neurospheres from WT-Tg mice increased
accordingly due to increases in the FGF-2 concentrations.
However, FGF-2 concentrations had no effect on the number
of neurospheres from Hspg2−/−-Tg (Fig. 7A). We also found
that Hspg2−/−-Tg neurospheres were significantly smaller
(WT-Tg: 83.3 ± 1.58 μm; Hspg2−/−-Tg: 52 ± 0.86 μm, Fig. 7B).
The basal phosphorylation level of Akt in Hspg2−/−-Tg
neurosphereswas slightly less than that inWT-Tg neurospheres,
Figure 7 Perlecan is necessary for FGF-2 promotion of neurosphere formation. (A) Low density primary neurosphere culture in the
presence of EGF (20 ng/ml) and different concentrations of FGF-2 (0, 20, 200 ng/ml). In the absence of perlecan, FGF-2 fails to promote
neurosphere formation. The data are expressed as means ± SEM (n = 6, *** indicates P-value of P b 0.0001; ** indicates P-value of P b 0.001;
one way analysis of variance followed by Bonferroni's multiple comparison test). (B) Bright field images of the primary neurosphere culture
after 1 week in vitro. The average size of neurospheres from perlecan-deficient brain is significantly smaller (WT-Tg: 83.3 ± 1.58 μm;
Hspg2−/−-Tg: 52 ± 0.86 μm; p b 0.0001). Scale bar: 150 μm. (C) Neurospheres were immunoblotted with indicated antibodies. (D, E) FGF-2
stimulation of Akt and Erk1/2 pathways is impaired in the absence of perlecan. (F) In the absence of perlecan, cyclin D2 expression is
significantly reduced and is not responsive to FGF-2 stimulation. (D–F) The data are expressed asmeans ± SEM (n = 3, *** indicates P-value of
P b 0.001, ** indicates P-value of P = 0.0019. (G) Proposed mechanism of the perlecan function in FGF-2-dependent neurogenesis. In the
presence of perlecan, FGF-2 activates Akt and Erk1/2 pathways and increases cyclin D2 expression leading to the progression of the cell cycle
thus allowing NSCs self renewal and neurogenesis. In absence of perlecan, this series of event is greatly impaired.
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between Hspg2−/−-Tg and WT-Tg neurospheres (Fig. 7C–E).
The addition of FGF-2 at a high concentration (200 ng/ml)
to the culture induced a significant increase in the phosphor-
ylation levels of both Akt and Erk1/2 in the WT-Tg mice,
whereas this FGF effect was much less in Hspg2−/−-Tg
mice (Fig. 7C–E). Furthermore, the expression of cyclin D2
was less in Hspg2−/−-Tg neurospheres than the level in WT-Tg
neurospheres (Fig. 7F). The high concentration of FGF-2
also significantly increased cyclin D2 expression in WT-Tg
neurospheres. In Hspg2−/−-Tg neurospheres, the level of
induction of the cyclin D2 expression by FGF was less than
that in WT-Tg neurospheres (Fig. 7 F). Hence, we propose
in Fig. 7 G that perlecan is necessary for FGF-2 to activatethe Akt and Erk1/2 pathways, thus leading to cyclin D2
expression, cell cycle progression, and ultimately NSCs
self-renewal and proliferation. Taken together, our results
strongly suggest that perlecan affects FGF-2 dependent
maintenance of NSCs.
Discussion
Extracellular matrix in the neurogenic niche of
Hspg2−/−-Tg mice
We previously reported some disparities in the composition
of ECM components in fractones and nearby capillaries when
503Perlecan is required for FGF-2 signaling in the neural stem cell nichethese were compared with blood vessels outside the SVZ.
Laminin α1 (Lama1) is present in large (N25 μm of diameter)
arteries and arterioles, while other basement membrane
molecules, such as laminin β1 (Lamb1), perlecan, collagen
IV, and nidogen, are present in all blood vessels and in
fractones (Mercier et al., 2002). We also reported that 10E4
antibody staining for heparan sulfate chains was primarily
observed in fractones and in SVZ blood vessels (Kerever et
al., 2007; Mercier and Arikawa-Hirasawa, 2012; Douet et al.,
2013). In the present study, we showed that agrin was
expressed in fractones and in blood vessel basement
membranes (as we previously reported for perlecan), but
that collagen 18 was only expressed in blood vessels from
adjacent neural nuclei. We found that all three different
antibodies to HS chains stained fractones and SVZ blood
vessels, and these showed no obvious changes in their
expression patterns in the absence of perlecan. It is unlikely
that collagen 18 compensates for perlecan loss to maintain
those HS chains because it was absent in the neurogenic
niche. Agrin most likely accounts for this staining, since it is
a proteoglycan that bears heparan sulfate chains. Therefore,
our data suggest that HS chains and/or the protein core of
perlecan are involved in neurogenesis because the absence
of perlecan greatly impaired neurogenesis.Neural stem cell maintenance
A specific marker for the identification of NSCs is still
lacking because most recognized markers are also expressed
by other cell types. Therefore, we used a combination of
CD133 and GFAP, two markers present in NSCs. GFAP and
CD133 can be found in SVZ astrocytes and in ependymocytes,
respectively. The use of both markers allowed us to
characterize a specific cell population. Type B cells frequently
penetrate the ependymal layer to contact the ventricle
(Mirzadeh et al., 2008; Shen et al., 2008). Indeed, we
observed that CD133+GFAP+ cells often extended processes
contacting the ventricle where CD133 was absent in
ependymal cells (Fig. 2B). One possible explanation for the
decrease in CD133+ NSCs in the perlecan-deficient brain may
be that perlecan serves as a survival factor. Staining for an
apoptosis marker, single-stranded DNA (SSDNA), showed
negligible cell death in the SVZ of WT-Tg and Hspg2−/−-Tg
mice (Supplemental Fig. 4), similar to that in the SVZ of wild
type mice as reported (Shen et al., 2008). Notably, some
CD133− cells also share NSC properties (Sun et al., 2009), and
CD133 is expressed in type B1 cells, a subpopulation of type B
cells that function as NSCs (Mirzadeh et al., 2008). Both NSC
populations (CD133+GFAP+ and CD133−GFAP+) may therefore
coexist in the adult SVZ. However, the necessity of CD133
expression for differentiation is unknown. Sun et al. reported
that the CD133− NSC population is mainly in the G0/G1 phase,
while the CD133+ NSC population is evenly split between
GO/G1 and G2/M. Moreover, when cultured, the progeny of
this CD133− NSC population reacquired CD133. This suggests
that a transition from a quiescent CD133− NSC into a CD133+
NSC is possible in vitro.
Cyclin D2 is a G1 active cyclin that is necessary for the
progression of the cell cycle. The lack of functional cyclin D2
leads to a critically impaired adult neurogenesis (Kowalczyk,
2004). Here we observed that in the absence of perlecan,cyclin D2 expression was significantly reduced both in vivo and
in vitro. These results further suggest that perlecan is
necessary for the cyclin D2-mediated progression of the NSC
cell cycle.
We observed a reduction in the numbers of type C and
type A cells in the SVZ, but this reduction was proportional
to the decrease in CD133 + GFAP + NSCs in the absence of
perlecan. If perlecan was involved in the differentiation
process into type A cells, we would have expected a
stronger decrease in the population of new neuroblasts in
the SVZ. Our results suggest that perlecan was not necessary
to amplify type C cells or to differentiate into type A cells,
but that it was necessary to maintain the population of
NSCs.
We found that the decrease in the size of the RMS in
Hspg2−/−-Tg mice was equivalent to the decreased number of
type A cells exiting the SVZ. Therefore, perlecan may not be
necessary for the migration of neuroblasts. Once neuroblasts
arrive in the olfactory bulb, the majority of them start to
differentiate into mature neurons in the granule cell layer.
Others migrate further to the glomerular layer, where they
differentiate into periglomerular neurons. We observed a
decrease in the integration of new neurons into the olfactory
bulb in both the granule cell layer and the glomerular layer in
Hspg2−/−-Tg mice. These results are consistent with the
decrease in numbers of CD133+GFAP+ NSCs, which resulted in
a decrease in new neurons integrating into the olfactory bulb.
Perlecan is involved in angiogenesis through the binding and
modulation of growth factor activity (Aviezer et al., 1994;
Ishijima et al., 2012). Removal of perlecan HS chains causes
impaired tumor angiogenesis and tumor growth (Zhou, 2004).
CD133+ cancer stem cells have been identified as a critical cell
population for resistance to chemotherapy (Liu et al., 2006).
Our findings in the present study that perlecan is critical for
CD133+ NSCs, open the question of whether perlecan plays a
role in the maintenance of CD133+ cancer stem cells.FGF-2 stimulation of neurogenesis is impaired in the
absence of perlecan
In this study, we showed that the ability to form neurospheres in
response to FGF-2 stimulation was less effective in the absence
of perlecan. Furthermore, the activation of Akt and Erk1/2, two
major downstream signaling pathway of FGF-2, was critically
impaired both in vivo and in vitro in the absence of perlecan.
Furthermore, cyclin D2 expression which has been shown to be
positively regulated by the activation of the Akt and Erk
pathways (Dey et al., 2000; Fatrai et al., 2006), also failed to
increase following FGF-2 stimulation in neurospheres derived
from perlecan-deficient mice. Hence, we proposed that the
absence of perlecan critically affects FGF-2 signaling, which
results in reduced cyclin D2 expression and eventually a
significant decrease in the NSC self-renewal and neurogenesis.
Chondroitin sulfate (CS) glycosaminoglycans have also been
suggested to play a role in FGF-2 signaling (Filla et al., 1998;
Hagihara et al., 2000; Sirko et al., 2010). We previously
reported that fractones and SVZ blood vessels specifically
capture FGF-2 from the extracellular milieu (Kerever et al.,
2007). However, we did not detect CS chains in the fractones
and in the SVZ blood vessels of either the WT-Tg or the
Hspg2−/−-Tg mice. Furthermore, FGF-2 localization was
504 A. Kerever et al.correlated with cells expressing perlecan but not with cells
expressing CS chains in neurospheres. These results suggest
that perlecan is the major proteoglycans responsible for
the management of heparin-binding growth factors, such as
FGF-2, in the neurogenic niche.
An extracellular matrix niche for neurogenesis
Previous studies have introduced the concept of the vascular
niche for neurogenesis in the SVZ (Shen et al., 2008; Tavazoie
et al., 2008; Kojima et al., 2010). At the vascular basement
membrane interface, the fate of NSCs is influenced by signals
diffusing from endothelial cells (Shen et al., 2008), and also by
signals traveling through the blood–brain barrier (Tavazoie et
al., 2008). The contact between α6β1 integrins of NSCs and
laminin in the blood vessel basement membrane is crucial for
the positioning and proliferation of NSCs (Shen et al., 2008;
Tavazoie et al., 2008). In addition, fractones have been
implicated as crucial niche components that are tightly
associated with NSCs (Mercier et al., 2002, 2003; Kerever et
al., 2007; Mercier and Arikawa-Hirasawa, 2012; Douet et al.,
2013). Growth factors, such as FGF-2 and BMP-7, in the
cerebrospinal fluid may penetrate the ependymal wall
through the interstitial cleft, a structure identified by MW.
Brightman (1965; 2002) and can be captured by fractones
(Kerever et al., 2007; Douet et al., 2012) to regulate adult
neurogenesis (Douet et al., 2012; Douet et al., 2013).Since
both fractones and SVZ blood vessels contain perlecan, it is
likely to be involved in modulating signaling from the blood
vessels and from the cerebrospinal fluid. We showed that
FGF-2-promoted neurogenesis is impaired in the absence of
perlecan. Taken together, these results strongly suggest that
perlecan regulates neurogenesis by modulating the growth
factor activity in the neurogenic niche. Our study revealed
that perlecan is a critical extracellular matrix component of
the neurogenic niche with multiple functions in development
and in maintaining tissue.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.scr.2013.12.009.
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